1-year outcomes with the Absorb bioresorbable scaff old in patients with coronary artery disease: a patient-level, pooled meta-analysis

Background Compared with metallic drug-eluting stents, bioresorbable vascular scaffolds (BVS) offer the potential to improve long-term outcomes of percutaneous coronary intervention. Whether or not these devices are as safe and effective as drug-eluting stents within the first year after implantation is unknown.

2016

08-12

First-in-man Implantation of the XINSORB Bioresorbable Sirolimus-eluting Scaffold in China

To the Editor: A 35-year-old man who smoked for 15 years suffered from chest pain 12 days ago before admission. He was diagnosed as myocardial infarction. Thrombolytic therapy was given consequently. The electrocardiogram showed sub-acute inferior wall myocardial infarction. Echocardiogram showed attenuated constriction of the inferior wall with an ejection fraction of 59%. On September 5, 2013, he was treated with a XINSORB scaffold in right coronary artery (RCA).

2016

08-12

Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents:single-center experience

To assess the midterm efficacy of a biodegradable poly-l-lactic acid (PLLA) stent in the treatment of superficial femoral artery (SFA) occlusive disease.

2016

08-12

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease

In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent presence of the metallic stent frame in the coronary-vessel wall. Bioresorbable vascularscaffolds have been developed to attempt to improve long-term outcomes.

2016

08-12

Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks

　Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement.

2016

08-12

A bioresorbable everolimus-eluting scaff old versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II)...

Background Despite rapid dissemination of an everolimus-eluting bioresorbable scaffold for treatment for coronary artery disease, no data from comparisons with its metallic stent counterpart are available. In a randomised controlled trial we aimed to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent. Here we report secondary clinical and procedural outcomes after 1 year of follow-up.

2016

08-12

Evaluation of the Biodegradable Peripheral Igaki-Tamai Stent in the Treatment

This study sought to evaluate the safety and performance of the Igaki-Tamai (Igaki Medical Planning Company, Kyoto, Janpan) biodegradable stent in patients with occlusive superficial femoral artery (SFA) disease.

2016

08-12

新型钴鉻合金可(kě)降解塗層西羅莫司洗脫支架在豬冠狀動脈過度擴張模型中對新生(shēng)內(nèi)膜的影(yǐng)響

評價L-605 钴鉻合金支架平台、聚丙交酯- 乙交酯(PLGA)共聚物載體(tǐ)西羅莫司藥物洗脫支架在小(xiǎo)型豬冠狀動脈過度擴張模型中的安全性和(hé)有(yǒu)效性。

2016

08-12

Stent thrombosis with drug-eluting stents: is the paradigm shifting?

First-generation drug-eluting stents (DES), which impart the controlled release of sirolimus or paclitaxel from durable polymers to the vessel wall, have been consistently shown to reduce the risk of restenosis and target vessel revascularization compared with bare metal stents (BMS).

2016

08-12

Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial

First generation drug-eluting stents (DES) were associated with a high incidence of late stent thrombosis (ST), mainly due to delayed healing and re-endothelization by the durable polymer coating. This study sought to assess the safety and efficacy of the Nano polymer-free sirolimus-eluting stent (SES) in the treatment of patients with de novo coronary artery lesions.

2016

08-12

< 12 > 前往 頁

公司信息

北京飛渡醫療器械有限公司

Beijing Advanced Medical Technologies,Ltd.Inc.

 

聯系我們

地址：北京市大(dà)興區(qū)永旺西路26号院中關村醫(yī)療器(qì)械園11号樓

電(diàn)話(huà)：010-6297-7955             郵箱：amt@ametcorp.com

圖片名稱

微信聯系

@Copyright 2022 北京飛渡醫療器械有限公司 All rights reserved   版權所有(yǒu)

京ICP備11028039号    網站(zhàn)建設：中企動力  南京